Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 18/20 | 0.73 |
| ▸ | MMP1 | P03956 | 17/20 | 0.73 |
| ▸ | PGR | P06401 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone Benzoate SCHEMBL11877997 | 0.92 | NR3C1 (0.77) | NR3C1MMP1PGRMEN1USP2 | |
| Betamethasone Benzoate SCHEMBL49469 | 0.92 | NR3C1 (0.77) | NR3C1MMP1PGRMEN1USP2 | |
| Betamethasone Benzoate SCHEMBL2954925 | 0.92 | NR3C1 (0.77) | NR3C1MMP1PGRMEN1USP2 | |
| Betamethasone Benzoate SCHEMBL11878006 | 0.92 | NR3C1 (0.77) | NR3C1MMP1PGRMEN1USP2 | |
| SCHEMBL1437695 | 0.91 | NR3C1 (0.70) | NR3C1MMP1PGRMEN1USP2 | |
| Betamethasone Benzoate SCHEMBL21682645 | 0.91 | NR3C1 (0.77) | NR3C1MMP1PGRMEN1USP2 | |
| SCHEMBL11812693 | 0.88 | NR3C1 (0.83) | NR3C1MMP1PGRMEN1USP2 | |
| SCHEMBL6986508 | 0.88 | NR3C1 (0.83) | NR3C1MMP1PGRMEN1USP2 | |
| SCHEMBL7547 | 0.88 | NR3C1 (0.83) | NR3C1MMP1PGRMEN1USP2 | |
| SCHEMBL147590 | 0.88 | NR3C1 (0.82) | NR3C1MMP1PGRMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 643 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295608-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | INSIGNIA PHARMACEUTICALS, LLC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250288599-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | INSIGNIA PHARMACEUTICALS, LLC (US) | 2025-09-18 | — | — | US | claimed |
| CN-115463084-B | Compound oil solution preparation for long-acting analgesia and preparation method thereof | 北京泰德制药股份有限公司 | 2024-05-28 | — | — | CN | claimed |
| EP-4214183-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | Essa Pharma, Inc. (CA) | 2023-07-26 | — | — | EP | claimed |
| US-20230210868-A1 | Methods of Treatment Using ICAM-Modulating Agents | AVM BIOTECHNOLOGY, LLC (US) | 2023-07-06 | — | — | US | claimed |
| CN-115463084-A | Compound oil solution preparation for long-acting analgesia and preparation method thereof | 北京泰德制药股份有限公司 | 2022-12-13 | — | — | CN | claimed |
| CN-111529684-A | Use of oral sustained release compositions containing cyclosporin | 卓越治疗有限公司 | 2020-08-14 | — | — | CN | claimed |
| US-9980902-B2 | Method for treating intestinal fibrosis | SIGMOID PHARMA LIMITED (IE) | 2018-05-29 | — | — | US | claimed |
| EP-2914311-B1 | METHOD OF TREATING VASCULAR DISEASE IN DIABETIC PATIENTS | ABBOTT CARDIOVASCULAR SYSTEMS INC (US) | 2017-06-28 | — | — | EP | claimed |
| EP-3091967-A1 | COMPOSITIONS FOR USE IN THE TREATMENT OF ULCERATIVE COLITIS | Sigmoid Pharma Limited (IE) | 2016-11-16 | — | — | EP | claimed |
| US-20100082095-A1 | Coatings Including Dexamethasone Derivatives And Analogs And Olimus Drugs | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2010-04-01 | — | — | US | claimed |
| US-20080038316-A1 | Conveniently implantable sustained release drug compositions | RAMSCOR, INC. | 2008-02-14 | — | — | US | claimed |
| US-20060258735-A1 | 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | MENG CHARLES Q | 2006-11-16 | — | — | US | claimed |
| US-7078431-B2 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS, INC. (US) | 2006-07-18 | — | — | US | claimed |
| WO-2005065185-A2 | TEMPERATURE-STABLE FORMULATIONS, AND METHODS OF DEVELOPMENT THEREOF | COLLEGIUM PHARMACEUTICALS, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050153946-A1 | Temperature-stable formulations, and methods of development thereof | COLLEGIUM PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | US | claimed |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS PHARMACEUTICALS, INC. | 2003-12-25 | — | — | US | claimed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | claimed |
| EP-1330448-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | Atherogenics, Inc. (US) | 2003-07-30 | — | — | EP | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | VCAM1, ICAM1, ITGB1 | NR3C1 109/4885MMP1 161/4885PGR 639/4885 |
| US-20060258735-A1 | 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | VCAM1, ICAM1, ITGB1 | NR3C1 109/4885MMP1 161/4885PGR 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.